Study: Don’t Delay Platinum Re-Challenge in Ovarian Cancer

October 13, 2017 7:57 pm

Don’t delay platinum-based chemotherapy in favor of single-agent non-platinum-based chemotherapy in patients with partially platinum-sensitive ovarian cancer, Italian researchers advised.

Introducing non-platinum chemotherapy to prolong the platinum-free interval (PFI) in patients with progressing ovarian cancer who experience disease recurrence, or … Read more

Knowledge and Good Decision Making Tools for Ovarian Cancer Patients

March 8, 2017 11:00 pm

By: Annette McElhiney

As a retired college professor, I firmly believe that knowledge is power and may also result in a longer healthier life. In a recent Wall Street Journal article, “How to Get Patients to Take More Control Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more